Clarus Biologics Inc. is pioneering advancements in vaccine and immunotherapy technologies through its innovative use of Virus-Like Particles (VLP), specifically its lead product, CBI-3A. This novel VLP is designed to enhance the safety and efficacy of recombinant antigen vaccines by stimulating immune responses across all three elements of the adaptive immune system—antibody, T-cell, and mucosal immunity. CBI-3A operates by mimicking a natural viral infection, which triggers a robust innate immune response, thereby improving the overall immune response to the vaccine antigen. This mechanism not only increases the effectiveness of the vaccine but also allows for dose-sparing capabilities, significantly reducing the amount of vaccine needed while maintaining high levels of protection.

The versatility of CBI-3A has been demonstrated through extensive pre-clinical studies across multiple animal species, showing its ability to elicit strong immune responses and provide significant protection against various pathogens. Importantly, the VLP has shown no significant safety concerns in the studies conducted, positioning it as a promising solution to current challenges in vaccine development, such as limited immunogenicity and supply constraints. By leveraging the unique properties of CBI-3A, Clarus Biologics aims to address critical needs in the vaccine market, ultimately contributing to the development of safer and more effective prophylactic and therapeutic options.

United States

Clarus Biologics was launched to increase the availability of safe and effective prophylactic and therapeutic technologies. It’s lead product is a next-generation vaccine Virus Like Particle intended to enhance the effectiveness, efficiency and availability of vaccines.Clarus Biologics is Dedicated to the Discovery and Development of Novel Vaccine and Immunology Technologies

Clarus Biologics Inc.

Company Details